

Case Report on Adenocarcinoma of Rectum and Anal Canal.

Riya Aglawe¹, Ms. Bhawana Dhanvij², Aniket Pathade³, S. V. Rathkanthiwar⁴

1 Florence Nightingale Training College of Nursing, Sawangi Meghe, Wardha, Maharashtra;

Email: riyaaglawe@gmail.com.com,

2 Nursing Tutor, Florence Nightingale Training College of Nursing Sawangi (Meghe), Sawangi Meghe, Wardha;

Email: dhanvijbhawna@gmail.com,

3 Research Consultant, Jawaharlal Nehru Medical College, Datta Meghe Institute Of Medical Sciences, Wardha.

4Dept. of Electronics Engineering, Yeshwantrao Chavan College of Engineering, Nagpur. Email: svr_1967@yahoo.com

Abstract: -

Introduction: - Squamous cell carcinomas account for about 75% of anal canal tumours, while adenocarcinomas account for more than 20%. The epithelium of the anal canal, which comprises the mucosal surface, anal glands, and the lining of fistulous tracts, evolves into adenocarcinoma of the anal canal. Adenocarcinomas are malignant tumours with diseased cells grouped in the shape of glands. Adenocarcinomas, which start in the glandular cells of the stomach lining, are the most common type of stomach cancer. Adenocarcinoma is the most frequent kind of pancreatic cancer. Adenocarcinomas are malignant tumours that are organized in the form of glands. Adenocarcinomas start in the glandular cells of the stomach lining and progress to other parts of the body. Adenocarcinoma is also the most frequent form of pancreatic cancer. Cancers and tumorlike diseases of the anus and perianal region arise from the anal canal and anal border, or from tumours that have spread from other organs. The anal canal's structure is complicated, and its many histologic characteristics can contribute to a variety of pathologic diseases. From the anorectal junction to the anal margin, the anal canal runs. Anal canal cancers are divided into two categories by the World Health Organization: (a) anal intraepithelial neoplasia, which is the precursor to squamous cell carcinoma (SCC), and (b) invasive tumours. Epithelial tumours (SCC, adenocarcinoma, mucinous adenocarcinoma, small celiac adenocarcinoma, small celiac adenocarcinoma, small celiac adenocarcinoma, small celiac adenocarcinoma, small cell.

Clinical findings- A 56 year old male patient admitted in AVBR Hospital with the chief complaint of passing blood in stool since 1month, and pain white defecation since 1month, and bleeding per rectum for 1 month.

Therapeutic Interventions:- All the medication was given and all treatment was taken and the result were fine. Tab. Limcee, Cap. Beolin and Tab. Urimax administered as prescribed.

Adenocarcinoma of rectum and anal canal.

Outcome:- After the medication patient chief complaint vomiting, pain in abdomen, blood in stool is relieved, and pain while defecation was diminished.

Conclusion:- He responded to the medicine, antibiotics, analgesic and physical counselling.

The ampulla of Vater cancer has a higher resectability rate and a better prognosis than pancreatic carcinoma. Because lymph node status affects survival, it's critical to get a diagnosis as soon as possible. Long-term survival is also improved by careful operational dissection and the avoidance of transfusions. Anal adenocarcinoma has a terrible prognosis, and there is little information on how to treat it effectively. According to the studies, the best likelihood of survival is a combination of radical surgical resection and pre- or postoperative chemoradiotherapy.

Keywords: adenocarcinoma, anal canal

Introduction:

Anal canal adenocarcinoma is a rare malignancy with so little research on management and findings. The goal of this study is to see how well people with adenocarcinoma control their condition and how long they live. Adenocarcinoma is a kind of cancer that begins in your body's mucus-producing glandular cells. These glands can be found in a variety of organs, and adenocarcinoma can develop in any of them. The epithelium of the anal canal, which comprises the mucosal surface, anal glands, and the lining of fistulous tracts, evolves into adenocarcinoma of the anal canal. Anal canal

adenocarcinoma is a rare malignancy with so little research on management and findings. The cells that border the upper region of the anus near the rectum are where these tumours begin. They can also begin in the glands that leak fluids into the anal canal beneath the anal mucosa. Anal adenocarcinomas are treated similarly to rectal carcinomas in the majority of cases. Smoking, HIV infection, homosexuality, anal Crohn's disease, and chronic fistula-in-ano all are risk factors for anal adenocarcinoma. Colorectal cancer originating in the anal mucosa above the dentate line or extra mucosal (perianal) adenocarcinoma are two possibilities. Extra mucosal adenocarcinoma is an uncommon kind of adenocarcinoma defined by extra mucosal or intramural development without a lymph node.¹

Adenocarcinoma can develop in the glands that coat the insides of the organs and spread throughout the body. Adenocarcinoma is a cancer that develops in glandular epithelial cells, which release mucus, digestive juices, and other fluids. It's a subtype of carcinoma, which is the most prevalent type of cancer, and it usually manifests itself as solid tumours. According to the National Cancer Institute, adenocarcinomas are first noticed as a thicker, plaque-like white mucous membrane. They can easily spread through the soft tissue in which they occur. The prognosis for anal adenocarcinoma is dismal, and treatment options are still up for debate. A literature review was conducted to determine current practice in the management of anal adenocarcinoma. Anal canal cancers are classed as basaloid (essentially squamous in form, comparable to its homonym in the upper respiratory/digestive tract), epidermoid (similar to skin tumours), and adenocarcinomas with a line of development toward adenocarcinoma.²

Epidemiology:

Rectal Cancer is a type of cancer that affects the Age more than 50 years, obesity, physical inactivity, red or processed meat consumption, alcohol consumption, and smoking were once regarded to be non-inherited risk factors for colorectal cancer. Recently, researchers have looked into whether the risk factors for colon and rectal cancer alter when each main site is looked at separately. In a large prospective cohort research of more than 134,000 men and women, Wei et al found that family history and physical inactivity may not enhance the risk of rectal cancer as previously thought, and that these two factors primarily influence the risk of colon cancer.³

Although good outcomes have been reported in patients with neoplasms detected early in their progression, the clinical similarity with other benign diseases and the lower expression of the tumour component in the mucosa are the most common reasons for delay in diagnosis and, as a result, a poor prognosis. When compared to squamous carcinoma, a higher number of patients with anal canal ADC have advanced disease, distant metastasis, and, as a result, a lower overall survival. According to the National Cancer Data Base (NCDB), 9.8% of patients with anal ADC are in stage iv at the time of presentation, compared to 5% of squamous carcinomas.⁴

Patient Information:

Patient specific information: A 56 year old male patient visited AVBR Hospital with the chief complaint of vomiting, pain in abdomen, passing blood in stool, and pain while defecation for 1 month for further management. Present case visit AVBR Hospital on old basis with chief complaint passing blood in stool, and pain while defecation. Patient has no past medical / surgical history. He was mentally stable. He is an oriented person. He has maintained a good personal relationship with family members.

Primary concern and symptoms of the patient: A patient admitted AVBR Hospital on dated 5/7/2021 with chief complaint of vomiting, pain in abdomen, passing blood in stool and pain while defecation since 1month for further investigation patient was diagnosed Adenocarcinoma of rectum and anal canal.

Medical, Family and Psycho-social history: present case had no history of medical problem, he belongs to nuclear family and, he was mentally stable conscious orientated date time place, he had maintained good relationship with doctor and nurses as well as other patients also. He belongs to nuclear family. There are five members in his family. All family members are healthy except the patient. patient look anxious, depressed and confused.

Relevant past intervention with outcome:- Present case had no any bad medical history.

Clinical Findings: The patient was conscious and well oriented to date, time, place. His body built was moderate and he maintained good personal hygiene.

General Examination: state of health was unhealthy,
thin body built, but distension of necrosis the height of patient is 165 cm
weight is 55kg. her vital parameters are normal.

Timeline:- Present case has history of vomiting, pain in abdomen, blood in stool. He visited the Sewagram hospital in June 2020 for further management. MRI, CT scan, colonoscopy biopsy was done diagnosed as Adenocarcinoma of rectum and anal canal. And then follow up AVBR Hospital for further treatment. Patient was visited in AVBR Hospital on an old basis with chief complaints of vomiting, pain in abdomen, blood in stool for further management.

Diagnostic Assessment:-

Physical Examination:

General examination

State of health: unhealthy

General condition – not satisfactory

State of consciousness: conscious

Body built: Moderate

Hygiene: poor

General Parameter:

Height: 165cm

Weight: 55 kg

Vital parameter:

Blood pressure: 130/80mmhg

Temperature: 98.6 o F

Pulse: 100beats/min.

Respiration: 25 breath/ min.

SPO 2 : 97%

Systemic Examination

CVS – S 1 S 2 +

Respiratory: wheezing sound present on left side; abnormalities of rectum and anal canal are present. All routine blood tests are done. CT-Scan, MRI, colonoscopy biopsy was done.

Significant physical examination and important clinical finding:-

Abnormalities of rectum and anal canal.

Therapeutic interventions:-

Medical management was provided to the patient. Inj. PIPTAZ 4.5 mg route is intravenous 24 hourly. Tab. Limcee route is orally, antibiotic.

Nursing perspectives: Fluid was provided to maintain the fluid and electrolyte monitored heart rate and vital sign per hourly.

Follow up and outcome:

Patient had a history of vomiting, pain in the abdomen, passing blood in stool and they visited Sewagram hospital. MRI, CT Scan, colonoscopy biopsy was done. And detected a case of adenocarcinoma of rectum and anal canal. Patient was passing blood in the stool, and pain while defecation was referred to AVBR Hospital. After treatment, outcomes were satisfactory.

Discussion:-

This case shows the difficulties in diagnosing anal cancers early on, as well as the need of doing anoscopy and colonoscopy on the anorectal area as soon as symptoms of rectal bleeding or serosanguinous anal discharge are detected. On screening colonoscopy, the lesion showed as an anal tumour in a patient with a confirmed normal anorectal junction. 5 years in the past. This has been hypothesized following the detection of anal adenocarcinoma in patients with chronic local inflammatory diseases such as anal fistulas and inflammatory bowel disease (IBD). Other possibilities for the development of anal adenocarcinoma include cancer cells implantation from a more proximal location along the colon and the use of chronic immunosuppression in patients with the condition. Due to the anal malignancy's lack of differentiation, the likelihood of low rectal adenocarcinoma with extensive extension into the perianal skin rather than primary anal adenocarcinoma cannot be ruled out completely. The problems in diagnosing poorly differentiated anal carcinomas that spread to the rectum are illustrated in this example. The problems in diagnosing poorly differentiated anal carcinomas that spread to the rectum are illustrated in this example. Because the lesion most likely originated during that time, the colonoscopy result was most likely not a false negative. Asymptomatic people can have anal malignancies discovered during a normal screening colonoscopy. New symptoms, such as rectal bleeding or serosanguinous anal discharge, should be investigated. Studies on related aspects were reported⁷⁻¹².

Anal canal adenocarcinoma is a rare cancer that is associated with a bad prognosis. Squamous cell carcinomas account for the majority of anal canal malignancies, which are now treated with chemoradiation . As a result, until recently, the management of AA was not standardized and fragmented in practice, as suggested by NCCN guidelines . Because of the disease's rarity, the majority of studies in the literature were case series or case reports that were reported retrospectively. There is a scarcity of long-term follow-up evidence on this unique diagnosis. As a result of the disease's negative outcome.⁵

Conclusion:

The incidence of anal canal adenocarcinoma appears to be decreasing, according to our examination of the SEER database's anal canal adenocarcinoma data. In the elderly, the disease's prognosis is still bleak. It's also clear that there's a bimodal distribution of poor short-term cancer-free survival in younger and older patients. When compared to chemoradiation alone, surgical excision increases the chances of cure. Given the paucity of significant research in this subject, we believe multicenter trials on AA are necessary.

Rectal and anal cancers have separate pathologic characteristics, risk factors, staging, and therapy algorithms. Radiologists must be aware of these important characteristics in order to appropriately characterize the tumor's local-regional extent, paying particular attention to the sphincter complex, mesorectal fascia, peritoneum, surrounding organs, and pertinent lymph node stations. To ensure that our radiation oncology colleagues have the greatest possible information when formulating their radiation therapy treatment plan, the radiologist must appropriately examine each of these major areas of concern.⁶

References:

1. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. *Diseases of the colon & rectum*. 2009 Apr 1;52(4):624-31.
2. Oien KA. Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. University of Glasgow (United Kingdom); 2002.
3. Stoffel EM, Murphy CC. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. *Gastroenterology*. 2020 Jan 1;158(2):341-53.
4. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ER β expression as a common step in estrogen-dependent tumor progression. *Endocrine-related cancer*. 2004 Sep 1;11(3):537-51.
5. Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, Goodman KA. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. *Cancer*. 2011 Aug 1;117(15):3342-51.
6. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. *Radiology*. 2004 May;231(2):305-32.
7. Jaiswal, N., Makrande, J., Bhake, A., Bapat, A.V., 2019. Ema, vimentin, desmin, calretinin, e-cadherin on cell block to differentiate adenocarcinoma cells from benign reactive mesothelial cells. *International Journal of Pharmaceutical Research* 11, 1860–1864. <https://doi.org/10.31838/ijpr/2019.11.02.213>
8. Rinait, A., Lamture, Y.R., Prateek, P., Gode, D., 2020a. Surgery for gastric adenocarcinoma with hospital stay: A prospective study. *Indian Journal of Forensic Medicine and Toxicology* 14, 6211–6216. <https://doi.org/10.37506/ijfmt.v14i4.12570>
9. Diwedi, A.K., Khandare, K., 2020. A rare case of anal condyloma in AIDS patient. *Pan African Medical Journal* 37, 1–2. <https://doi.org/10.11604/pamj.2020.37.46.25397>
10. Abbafati, C., Abbas, K.M., Abbasi-Kangevari, M., 2020a. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 396, 1204–1222. [https://doi.org/10.1016/S0140-6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9)
11. Lozano, R., Fullman, N., Mumford, J.E., 2020. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019:

- a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 396, 1250–1284. [https://doi.org/10.1016/S0140-6736\(20\)30750-9](https://doi.org/10.1016/S0140-6736(20)30750-9)
12. Khatib, M.N., Shankar, A.H., Kirubakaran, R., Gaidhane, A., Gaidhane, S., Simkhada, P., Quazi, S.Z., 2018b. Ghrelin for the management of cachexia associated with cancer. *Cochrane Database of Systematic Reviews* 2018. <https://doi.org/10.1002/14651858.CD012229.pub2>